The first dose of Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) was administered today in Australia during a press briefing by The Hon Greg Hunt MP, Federal Minister for Health and Aged Care. Nuvaxovid is the first protein-based COVID-19 vaccine to receive approval for provisional registration by the Therapeutic Goods Administration (TGA).
The TGA granted approval for provisional registration of Nuvaxovid for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 18 years of age and older on January 19.
Novavax is proud to start delivering its vaccine to the people of Australia during a critical time as the pandemic shows no signs of retreat. Australia has played a pivotal role in Novavax’ Phase 1 and Phase 2 clinical trials supporting the development of Nuvaxovid. Additionally, a booster trial for Nuvaxovid and a Phase 1/2 trial for a combination seasonal influenza and COVID-19 vaccine are currently underway in Australia.
Novavax and the Commonwealth of Australia have an advance purchase agreement for 51 million doses of Nuvaxovid, with the option for an additional 10 million doses (up to 61 million doses total). Plans are actively underway to begin the delivery process for Nuvaxovid doses across Australia.
For more information on Nuvaxovid, including the Australian approved Product Information, Australian approved Consumer Medicines Information and Important Safety Information, or to request additional information please visit the following websites:
The brand name Nuvaxovid™ has not yet been authorized for use in the U.S. by the FDA. Novavax’ sponsor in Australia is Biocelect Pty. Ltd.
# # #